$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$ Reviva Pharmaceuticals Holdings (RVPH) Roth MKM analyst reiterated a Buy rating on Reviva Pharmaceuticals Holdings today and set a price target of $3.00. The company’s shares closed last Friday at $0.55. According to , Pachaiyappan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.2% and a 37.8% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Capricor Therapeutics, and Avidity Biosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $3.20 average price target, a 499.3% upside from current levels. In a report issued on September